Predict your next investment

SK Life Science company logo
HEALTHCARE | Pharmaceuticals / Drugs
sklifescienceinc.com

See what CB Insights has to offer

Founded Year

1993

About SK Life Science

SK Life Science is a global CNS-focused pharmaceutical company that promises to go beyond the expected to serve those affected by CSN disorders.

SK Life Science Headquarter Location

461 From Road 5th Floor

Paramus, New Jersey, 17652,

United States

Latest SK Life Science News

Cenobamate Continuation for Over 6 Years Represents Long-Term Efficacy and Safety

Jul 24, 2021

Cenobamate Continuation for Over 6 Years Represents Long-Term Efficacy and Safety Cenobamate In the long-term open-label extension of a randomized double-blind placebo-controlled study of adjunctive treatment for epilepsy with cenobamate (Xcopri; SK LIfe Science, Paramus, NJ)treatment duration averaged 6.25 years (200 mg median modal daily dose, range 50 to 400 mg). Initial enrollment was 149 adults who completed an earlier 12-week study, and as of July 2019, 57% (85/149) of participants continued being treated with cenobamate. "In this long-term evaluation with cenobamate, we observed high retention rates beyond 6 years in a real-life clinical setting in which patients received individualized doses of both cenobamate and other antiseizure medications (ASMs)," said Jaqueline French, MD, professor of Neurology, NYU Langone Comprehensive Epilepsy Center, director, Epilepsy Study Consortium, and chief medical and innovation officer, Epilepsy Foundation. "Because refractory epilepsy is a chronic, difficult to manage condition requiring ongoing treatment, the long-term retention rates represent an important and encouraging clinical outcome reflecting the safety, tolerability and effectiveness of cenobamate." At the completion of the 12-week period, 149 participants entered the extension treated with cenobamate along with 1 to 3 additional ASMs. The probability of continuing cenobamate for 6 years was 59%; among those who remained on cenobamate for at least 12 months (n=107), the probability of continuing for 6 years was 79%. The 54% (80/149) of participants who took cenobamate were able to discontinue 1 or more concomitant ASMs. The most common emergent adverse events were dizziness (33%), headache (27%), and somnolence (22%). The adverse events that lead to discontinuation in >1% of participants were fatigue (1%, 2/149), ataxia (1%, 2/149), and memory impairment or amnesia (1%, 2/149). Diseases & Diagnosis

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SK Life Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SK Life Science Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.